Business
Vivasure Medical Announces Acquisition by Haemonetics Corporation
GALWAY, Ireland, January 09, 2026--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones.
About this update from Haemonetics Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":350,"url":"https://media.zenfs.com/en/business-wire.com/91faefde42c13024e3dce45b0ae8e32b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V8grdIj0deprcnzGgbywRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/91faefde42c13024e3dce45b0ae8e32b","width":480,"height":350}},"lazy":false},{"type":"text","content":"GALWAY, Ireland, January 09, 2026--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones.","length":330,"tagName":"p"},{"type":"text","content":"Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery. In 2022, Vivasure Medical received a strategic investment from Haemonetics, which included an option to acquire Vivasure Medical.","length":363,"tagName":"p"},{"type":"text","content":"Earlier this year, Vivasure Medical announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures, building upon the successful results of the PATCH study as well as positive clinical use in Europe. The company previously received European CE mark approval for an expanded indication for PerQseal Elite, covering large-bore venous closure following its first CE mark approval for arterial procedures, positioning PerQseal Elite as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure.","length":660,"tagName":"p"},{"type":"text","content":""We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians who supported Vivasure’s mission," said Andrew Glass, CEO of Vivasure Medical. "Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits...